Today: 3 June 2026
Marvell stock on watch: Jefferies sticks with $120 target as traders line up Tuesday’s reopen
19 January 2026
2 mins read

Marvell stock on watch: Jefferies sticks with $120 target as traders line up Tuesday’s reopen

NEW YORK, Jan 18, 2026, 18:42 EST — The market has closed.

  • Jefferies maintained its buy rating on Marvell, holding the price target at $120 as markets prepare to reopen Tuesday following the holiday break.
  • Marvell shares ended Friday slightly higher, up 0.1% to $80.46.
  • Traders are gearing up for a packed week of earnings reports alongside new trade developments that might shake risk appetite.

Shares of Marvell Technology, Inc. (MRVL.O) are set to resume trading Tuesday following Jefferies’ decision to maintain a buy rating and a $120 price target on the chipmaker, a Futu News report says. The stock ended Friday at $80.46, edging up 0.1%.

The timing is crucial as the tape has been volatile even without fresh company updates. U.S. stocks closed nearly flat on Friday after a jittery session, while the Philadelphia SE Semiconductor index climbed 1.2%, Reuters reported. Markets will remain closed Monday in observance of Martin Luther King Jr. Day. “Historically the middle part of January tends to be pretty choppy,” noted Bruce Zaro, managing director at Granite Wealth Management. Reuters

Trade tensions have flared up again. Reuters reported Sunday that President Donald Trump plans to impose an extra 10% tariff on imports from several European countries beginning Feb. 1. IG analyst Tony Sycamore warned markets are likely to open this week in “risk-off” mode. Reuters

Jefferies analyst Blayne Curtis named Broadcom, Nvidia, and Marvell as his top semiconductor picks for 2026, according to Barron’s. He reiterated Broadcom (AVGO) as his “Top Pick” but noted Nvidia (NVDA) now looks undervalued. Curtis held Marvell at a $120 target, lifted Nvidia’s price target from $250 to $275, and kept Broadcom steady at $500. He pointed to Marvell’s AI chip business as a key factor that could expand its customer base. Barron’s

Price targets reflect analysts’ predictions for where a stock might land within the next year. Jefferies has set its target at $120, roughly 49% higher than Friday’s closing price. That’s a sizable gap for a stock that tends to move on changes in data-center spending chatter.

Marvell is positioning itself as a major player in AI infrastructure, particularly around networking. On Jan. 6, the company announced plans to acquire networking gear maker XConn Technologies for about $540 million. CEO Matt Murphy called the deal a move toward “a compelling switching platform for accelerated infrastructure,” referring to the critical switches that route data inside data centers. Reuters

In November, Marvell struck a $3.25 billion deal to acquire optical networking startup Celestial AI, doubling down on photonics—a technology that uses light to transfer data—as AI demands surge. “We’re going to have a silicon photonics powerhouse at Marvell,” said Murphy. Reuters

The company is also part of a wider supply-chain shift away from China. On Friday, Vietnam’s military-controlled Viettel kicked off construction of the nation’s first semiconductor fab. Reuters highlighted Marvell as one of the international chipmakers active in Vietnam’s testing and packaging sector.

But the stock isn’t without vulnerabilities. Marvell goes head-to-head with well-funded competitors — Broadcom peddles custom chips and networking gear, while Nvidia is increasingly integrating networking and systems with its AI processors. Investors have also shown concern over the “lumpiness” in custom ASIC orders, those chips designed for specific tasks, especially from major cloud clients. Reuters

Next week promises a mix of influences on chip stocks, even before Marvell’s next report. Netflix will release its earnings on Jan. 20, followed by Johnson & Johnson on Jan. 21. Intel’s results come after the close on Jan. 22 — all key indicators traders watch for clues on tech demand and corporate spending trends.

Marvell’s next major event is its earnings report, scheduled for March 4, 2026, according to Nasdaq’s calendar—though the company itself hasn’t confirmed the date. The real test arrives earlier: Tuesday’s open. Traders will be eyeing whether the chip rally and that recent $120 call can stay intact in a market that’s quick to pull back.

Latest articles

Archer Aviation trades under $7 as next test looms for air-taxi gamble

Archer Aviation trades under $7 as next test looms for air-taxi gamble

3 June 2026
Archer Aviation shares dipped below $7 premarket after closing at $6.74, as investors weigh heavy cash burn—$217.7 million Q1 net loss, $1.78 billion cash on hand—against hopes for first U.S. eVTOL flights this year; Cantor Fitzgerald cut its price target to $11 but kept an Overweight rating, while 46 disclosed risks and ongoing certification challenges cloud near-term outlook.
Broadcom’s $280 Billion AI Rally Hits Key Test

Broadcom’s $280 Billion AI Rally Hits Key Test

3 June 2026
Broadcom’s stock soared 14% in four days, adding $280 billion in value ahead of Wednesday’s earnings after Alphabet’s $80 billion equity raise spotlighted AI data-center suppliers; with options implying a 9% share move either way, investors await proof that surging AI demand is translating into real revenue growth.
J-Star Stock Moves Up After Texas Battery Update in Pre-Market

J-Star Stock Moves Up After Texas Battery Update in Pre-Market

3 June 2026
J-Star Holding Co. surged to $1.36 in premarket trading after new disclosures on its proposed $122.5 million Baytown, Texas solid-state battery plant, pushing shares above Nasdaq’s $1 minimum less than a week before a key shareholder vote on a reverse split aimed at regaining compliance.
Legend Biotech jumps 42% as traders look at results from small cancer study

Legend Biotech jumps 42% as traders look at results from small cancer study

3 June 2026
Legend Biotech shares soared 42% to $36.28 after early Phase 1 data showed all six higher-dose patients with relapsed or refractory B-cell non-Hodgkin lymphoma responded to its in vivo CAR-T therapy LB2501, with five complete responses; UBS raised its price target to $49, citing the therapy’s outlook, but the results are early and based on a small group with short follow-up.
T1 Energy Stock Falls Premarket After $32M KORE Battery Deal

T1 Energy Stock Falls Premarket After $32M KORE Battery Deal

3 June 2026
T1 Energy shares fell 1.3% premarket after announcing a $32 million KORE Power acquisition to expand into battery storage and AI data-center infrastructure, just a day after a 15.7% stock surge; Northland initiated coverage with an outperform rating and $16 target, but flagged deal execution and funding as key risks.
Qualcomm stock price slips into long weekend as investors eye dividend, board change and earnings
Previous Story

Qualcomm stock price slips into long weekend as investors eye dividend, board change and earnings

Coherent stock price in focus as COHR heads for Tuesday restart after product flurry
Next Story

Coherent stock price in focus as COHR heads for Tuesday restart after product flurry

Go toTop